Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept plus PRP for severe nPDR
NCT03863535Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jan 2019
- Primary completion
- Jan 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Randomised, open-label trial of conbercept (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Best-Corrected Visual Acuity at 12 months. Status: unknown.
02
Drugs
conbercept
Beyond the preview
Go deeper on NCT03863535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863535.